| Rise Therapy, Llc. | |
|
306 Park Ave Charles City IA 50616-3130 | |
| (319) 230-3406 | |
| Not Available |
| Full Name | Rise Therapy, Llc. |
|---|---|
| Speciality | Clinic/center - Mental Health (including Community Mental Health Center) |
| Location | 306 Park Ave, Charles City, Iowa |
| Authorized Official Name and Position | Rae Lynne Chase (MANAGER/OWNER) |
| Authorized Official Contact | 3192303406 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Rise Therapy, Llc. 306 Park Ave Charles City IA 50616-3130 Ph: () - | Rise Therapy, Llc. 306 Park Ave Charles City IA 50616-3130 Ph: (319) 230-3406 |
| NPI Number | 1922741685 |
|---|---|
| Provider Enumeration Date | 04/19/2022 |
| Last Update Date | 04/23/2022 |
| Certification Date | 04/23/2022 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922741685 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0801X | Clinic/center - Mental Health (including Community Mental Health Center) | (* (Not Available)) | Primary |
News Archive
Researchers at the National Institute of Standards and Technology (NIST) have developed a new chemical analysis method that has assisted researchers at the National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, in demonstrating a potentially important chemical link between alcohol consumption and cancer.
Implementing structured exercise training, including aerobic, resistance or both, was associated with a greater reduction in hemoglobin A1c levels for patients with diabetes compared to patients in the control group, and longer weekly exercise duration was also associated with a greater decrease in these levels, according to results of an analysis of previous studies, published in the May 4 issue of JAMA.
The World Gold Council (WGC) is delighted with the successful phase 1 clinical trial of a unique nanomedicine that uses nanoparticles of gold as the core of a delivery system for tumour targeted drug delivery.
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Company's Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.
› Verified 9 days ago